AMENDMENT TO JOINT VENTURE FOR R&D AGREEMENT
Exhibit 10.17
NOTE: PORTIONS OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF THE REDACTED LANGUAGE.
AMENDMENT TO JOINT VENTURE FOR R&D AGREEMENT
This amendment to Joint Venture for R&D Agreement (this “Amendment”) is entered into as of March 12, 2015, by and between Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. (“Yissum”) and Intec Pharma Ltd. (“Company”) (each to be referred to as a “Party” and together as the “Parties”).
| WHEREAS, | the Parties entered into a Joint Venture for R&D Agreement on June 1, 2000, which was extended and amended on October 5, 2004 and July 13, 2005 (the agreement and its amendments shall be referred together in this Amendment as the “Agreement”); and |
| WHEREAS, | in connection with the pending grant of a sublicense by the Company to Biogen Idec, the Parties wish to amend the Agreement as set forth herein, to become effective only with respect to such sublicense to be granted to Biogen Idec, as of the date such sublicense agreement is executed with Biogen Idec; |
NOW, THEREFORE, the Parties hereto, intending to be legally bound, hereby agree as follows:
Except as specifically defined herein, all terms used in this Amendment shall have the meaning ascribed to them in the Agreement.
| 1. | Amendment |
Effective as of the date of this Amendment, the Agreement shall be amended as follows:
| 1.1 | Section 2 of Appendix E of the Agreement shall be amended to read as follows: |
“The Company will pay Yissum Sublicense Fees during the Royalty Term at a rate of 15% of all Sublicense Consideration.”
| 1.2 | The following definitions will be added to Appendix E of the Agreement: |
“Royalty Term” means, on a country-by-country basis, a period of 15 years from the date of the First Commercial Sale in each country.
“Sublicense Consideration” shall mean any proceeds or consideration or benefit of any kind whatsoever that the Company or its Affiliate receives from a Sublicensee to the extent that such is a direct result of the grant of a Sublicense or an option to obtain such Sublicense, other than research and development funding that is actually used to cover the actual cost for research and development of a Product performed under the Sublicense agreement.
| 1.3 | The term “Distributor” and all references thereto (including within the Net Sales definition) shall be deleted. |
| 1.4 | The term “Product” shall be amended to read as follows: |
“Product” shall mean any product, process or service, the development, manufacture or sale of which exploits, comprises, contains, incorporates, is related to, or based on any of the patents and/or patent applications set forth in Exhibit 1.4 attached hereto.
| 1.5 | The Parties acknowledge and agree that (i) the patent applications and patents set forth on Exhibit 1.5(a) are solely owned by Yissum and are subject to an exclusive license by Yissum to the Company pursuant to the Agreement; and (ii) the Company is the sole and exclusive owner of the patents and/or patent applications set forth in Exhibit 1.5(b) and all inventions disclosed or claimed in such patents and patent applications (collectively, “Intec Technology”) and Yissum acknowledges that it has no ownership right or interest in or claim with respect to such Intec Technology apart from the right to receive Royalties and Sublicense Fees as provided in the Agreement. |
NOTE: PORTIONS OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF THE REDACTED LANGUAGE.
| 1.6 | Section 6(f) of the Agreement shall be amended to read as follows: |
“Any Sublicensee may sublicense the rights granted to such Sublicensee by the Company through multiple tiers without notice to or consent of Yissum, provided that such Sublicensee is Biogen Idec.”
| 1.7 | The following Section 15(f) shall be added to the Agreement: |
“15(f). In the event that the Agreement is terminated for any reason whatsoever, then, at the request of Biogen Idec, if it is not then in material default of the applicable Sublicense, Yissum shall enter into a new license agreement with Biogen Idec on substantially the same terms as Biogen Idec, provided, however, that such terms shall be amended, if necessary, to the extent required to ensure that such new agreement does not impose any obligations or liabilities on Yissum which are not included in or are greater in scope than Yissum’s obligations or liabilities under this Agreement”
| 1.8 | Yissum acknowledges and agrees that, notwithstanding the provisions of Section 6(e), Section 6(f) and Section 11(f) of the Agreement, Biogen Idec nor a Sub-sublicensee of Biogen Idec shall be required to enter into any direct undertaking or agreement of any kind with Yissum. |
| 2. | Effectiveness of Amended Agreement |
The Agreement, as amended hereby, shall continue in full force and effect as originally constituted and is hereby ratified and affirmed by the Parties.
IN WITNESS WHEREOF, the parties have caused this Third Amendment to be executed by their duly authorized representatives as of the date first written above.
| Yissum Research and Development | Intec Pharma Ltd. | |||
| Company of the Hebrew University | ||||
| of Jerusalem Ltd. | ||||
| By: | /s/ Xxxxxx Xxxxxxx and Xxxxxx Xxxxxx | By: | /s/ Xxxx Xxxxx | |
| Name: |
Xxxxxx Xxxxxxx – CEO and Xxxxxx Xxxxxx – VP Licensing, Pharmaceuticals |
Name: | Xxxx Xxxxx | |
| Title: | Title: | |||
NOTE: PORTIONS OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF THE REDACTED LANGUAGE.
Exhibit 1.4
| 1.Patent | Yissum Research Development Company of the Hebrew University of Jerusalem Gastroretentive Controlled Release Pharmaceutical Dosage Forms -(Client Case:IN-1-IL) - (0047465) |
| Country | App. No. | Our Ref. |
Filed | Patent No./ Publication No. |
Grant Date/ Pub. Date |
Next Renewal | ||||||
| Israel | 149853 | 1634914 | 20/11/2000 | 149853 | 01/04/2007 | 20/11/2018 | ||||||
| Patent Cooperation Treaty | PCT/IL00/00774 | 1635077 | 20/11/2000 | WO 01/37812 | 31/05/2001 | |||||||
| Australia | 16477/01 | 1635101 | 20/11/2000 | 783062 | 05/01/2006 | 20/11/2015 | ||||||
| Canada | 2,392,361 | 1635119 | 20/11/2000 | 2,392,361 | 19/01/2010 | 20/11/2015 | ||||||
| Japan | 2001-539427 | 0000000 | 20/11/2000 | 4679020 | 10/02/2011 | 10/02/2015 | ||||||
| United States of America | 10/157,325 | 1635143 | 20/11/2000 | 6,685,962 | 03/02/2004 | 03/08/2015 | ||||||
| South Africa | 200204268 | 1635150 | 20/11/2000 | 2002/4268 | 26/11/2003 | 20/11/2015 | ||||||
| European Patent Office | 00978993.4 | 1635168 | 20/11/2000 | 1235557 | 27/07/2005 | |||||||
| France | 00978993.4 | 1635572 | 20/11/2000 | 1235557 | 27/07/2005 | 30/11/2015 | ||||||
| Germany | 00978993.4 | 1635580 | 20/11/2000 | 60021604 | 27/07/2005 | 30/11/2015 | ||||||
| Spain | 00978993.4 | 1635598 | 20/11/2000 | 1235557 | 27/07/2005 | 30/11/2015 | ||||||
| Switzerland | 00978993.4 | 1635606 | 20/11/2000 | EP1235557 | 27/07/2005 | 30/11/2015 | ||||||
| Ireland | 00978993.4 | 1635630 | 20/11/2000 | 1235557 | 27/07/2005 | 30/11/2015 | ||||||
| Italy | 00978993.4 | 1635648 | 20/11/2000 | 1235557 | 27/07/2005 | 30/11/2015 | ||||||
| United Kingdom | 00978993.4 | 1635655 | 20/11/2000 | 1235557 | 27/07/2005 | 30/11/2015 |
NOTE: PORTIONS OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF THE REDACTED LANGUAGE.
| 2.Patent | Intec Pharma Ltd. Method and Apparatus for Forming Delivery Devices for Oral Intake of an Agent -(Client Case:IN-3-USP) -(0047512) |
| Country | App. No. | Our Ref. |
Filed | Patent No./ Publication No. |
Grant Date/ Pub. Date |
Next Renewal | ||||||
| United States of America | 60/759,554 | 1636661 | 18/01/2006 | |||||||||
| Patent Cooperation Treaty | IL2007/000070 | 1724418 | 18/01/2007 | WO2007/083309 | 26/07/2007 | |||||||
| European Patent Office | 07700757.3 | 1853217 | 18/01/2007 | 1981465 | 22/10/2008 | 31/01/2015 | ||||||
| Canada | 2,637,655 | 1853225 | 18/01/2007 | 18/01/2015 | ||||||||
| Israel | 192896 | 1853233 | 18/01/2007 | 192896 | 28/09/2013 | 18/01/2017 | ||||||
| Japan | 2008-550909 | 0000000 | 18/01/2007 | 5399715 | 01/11/2013 | 01/11/2016 | ||||||
| United States of America | 12/087,888 | 1853258 | 18/01/2007 | 8,298,574 | 30/10/2012 | 30/04/2016 | ||||||
| United States of America | 13/613,718 | 2181500 | 18/01/2007 | 8,753,678 | 17/06/2014 | 17/12/2017 | ||||||
| United States of America | 13/800,471 | 2214433 | 18/01/2007 | 8,609,136 | 17/12/2013 | 17/06/2017 | ||||||
| Japan | 2013-054912 | 0000000 | 18/01/2007 | 2013-129669 | 04/07/2013 | |||||||
| Israel | 226561 | 2228767 | 18/01/2007 | |||||||||
| Israel | 226563 | 2229192 | 18/01/2007 | |||||||||
| Israel | 226564 | 2229205 | 18/01/2007 | |||||||||
| United | ||||||||||||
| States of America | 14/305,600 | 2275337 | 18/01/2007 |
US-2014- 0360132 |
11/12/2014 |
NOTE: PORTIONS OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF THE REDACTED LANGUAGE.
| 3.Patent | Intec Pharma Ltd. A Gastro-Retentive System for the Delivery of Macromolecules -(Client Case:IN-4-USP) -(0047513) |
| Country | App. No. | Our Ref. |
Filed | Patent No./ Publication No. |
Grant Date/ Pub. Date |
Next Renewal | ||||||
| United States of America | 60/773,316 | 1636679 | 15/02/2006 | |||||||||
| Patent Cooperation Treaty | IL2007/000212 | 1731967 | 15/02/2007 | WO 2007/093999 | 23/08/2007 | |||||||
| European Patent Office | 07713260.3 | 1859727 | 15/02/2007 | 1991210 | 19/11/2008 | 28/02/2015 | ||||||
| Canada | 2,642,479 | 1859735 | 15/02/2007 | 2,642,479 | 19/08/2014 | 15/02/2015 | ||||||
| Israel | 193450 | 1859743 | 15/02/2007 | |||||||||
| United States of America |
12/223,965 | 1859750 | 15/02/2007 |
US-2009- 0304768 |
10/12/2009 |
| 4.Patent | Intec Pharma Ltd. Carbidopa/Lipodopa Gastroretentive Drug Delivery -(Client Case:IN-7-IL) -(060812) |
| Country | App. No. | Our Ref. |
Filed | Patent No./ Publication No. |
Grant Date/ Pub. Date |
Next Renewal | ||||||
| Israel | 208708 | 2051008 | 17/04/2009 |
NOTE: PORTIONS OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF THE REDACTED LANGUAGE.
| 4.Patent | Intec Pharma Ltd. Carbidopa/Lipodopa Gastroretentive Drug Delivery -(Client Case:IN-7-IL) -(060812) |
| Country | App. No. | Our Ref. |
Filed | Patent No./ Publication No. |
Grant Date/ Pub. Date |
Next Renewal | ||||||
| United States of America | 12/937,955 | 2144590 | 17/04/2009 | 8,771,730 | 08/07/2014 | 08/01/2018 | ||||||
| Patent Cooperation Treaty | PCT/IB2009/005691 | 2153336 | 17/04/2009 | WO 2009/144558 | ||||||||
| Canada | 2,721,493 | 2153341 | 17/04/2009 | 17/04/2015 | ||||||||
| China | 200980120103.9 | 2153353 | 17/04/2009 | CN102149369A | 10/08/2011 | |||||||
| European Patent Office | 09754186.6 | 2153363 | 17/04/2009 | 2276473 | 26/01/2011 | 30/04/2015 | ||||||
| India | 7638/DELNP/2010 | 2153372 | 17/04/2009 | |||||||||
| Japan | 2011-504573 | 0000000 | 17/04/2009 | |||||||||
| Japan | 0000000 | |||||||||||
| Republic of Korea | 00-0000-0000000 | 2153405 | 17/04/2009 | |||||||||
| South Africa | 2010/07797 | 2153411 | 17/04/2009 | 2010/07797 | 27/07/2011 | 17/04/2015 | ||||||
| Hong Kong | 11113197.1 | 2153823 | 17/04/2009 | 1158545 | 20/07/2012 | 17/04/2018 | ||||||
| United States of America | 14/322,436 | 2286884 | 17/04/2009 |
US-2014- 0314842 |
23/10/2014 | |||||||
| United States of America | 14/322,460 | 2286894 | 17/04/2009 |
US-2015- 0010624 |
08/01/2015 |
NOTE: PORTIONS OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF THE REDACTED LANGUAGE.
| 5.Patent | Intec Pharma Ltd. ZALEPLON GASTRORETENTIVE DRUG DELIVERY SYSTEM -(Client Case:IN-8-IL) -(060811) |
| Country | App. No. | Our Ref. |
Filed | Patent No./ Publication No. |
Grant Date/ Pub. Date |
Next Renewal | ||||||
| Israel | 213376 | 2127779 | 19/10/2009 | |||||||||
| Patent Cooperation Treaty | PCT/IB2009/007731 | 2153230 | 19/10/2009 | WO 0000/000000 | ||||||||
| Xxxxx | 200980153943.5 | 2153258 | 19/10/2009 | CN102300463A | 28/12/2011 | 19/10/2014 | ||||||
| European Patent Office | 09830077.5 | 2153268 | 19/10/2009 | 2378883 | 26/10/2011 | 31/10/2014 | ||||||
| India | 5067/DELNP/2011 | 2153278 | 19/10/2009 | |||||||||
| South Africa | 2011/04620 | 2153314 | 19/10/2009 | 2011/04620 | 28/03/2012 | 00/00/0000 | ||||||
| Xxxxxx Xxxxxx xx Xxxxxxx | 13/132,899 | 2153326 | 19/10/2009 |
US-2012- 0021051 |
26/01/2012 | |||||||
| Japan | 2014-231788 | 0000000 | 19/10/2009 |
NOTE: PORTIONS OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF THE REDACTED LANGUAGE.
| 6.Patent | Intec Pharma Ltd. Accordion pill comprising levodopa for an improved treatment of Xxxxxxxxx’x Disease symptoms -(Client Case:IN-11-USP) -(060810) |
| Country | App. No. | Our Ref. |
Filed | Patent No./ Publication No. |
Grant Date/ Pub. Date |
Next Renewal | ||||||
| United States of America | 61/408,985 | 2153012 | 01/11/2010 | |||||||||
|
Patent Cooperation Treaty |
PCT/IB2011/002888 | 2153034 | 01/11/2011 | WO 2012/059815 | 10/05/2012 | |||||||
| Canada | 2,815,959 | 2222633 | 01/11/2011 | 01/11/2015 | ||||||||
| European Patent Office | 11805936.9 | 2222641 | 01/11/2011 | 2635272 | 11/09/2013 | 30/11/2015 | ||||||
| India | 4158/DELNP/2013 | 2222652 | 01/11/2011 | |||||||||
| Israel | 226000 | 2222662 | 01/11/2011 | |||||||||
| United States of America | 13/882,768 | 2222675 | 01/11/2011 |
US-2014- 0017303 |
16/01/2014 |
| 7.Patent | Intec Pharma Ltd. “[***]” |
| Country | App. No. | Our Ref. |
Filed | Patent No./ Publication No. |
Grant Date/ Pub. Date |
Next Renewal | ||||||
| “[***]” | “[***]” | “[***]” | “[***]” |
NOTE: PORTIONS OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF THE REDACTED LANGUAGE.
| 8.Patent | Intec Pharma Ltd. “[***]” |
| Country | App. No. | Our Ref. |
Filed | Patent No./ Publication No. |
Grant Date/ Pub. Date |
Next Renewal | ||||||
| “[***]” | “[***]” | “[***]” | “[***]” |
| 9.Patent | Intec Pharma Ltd. “[***]” |
| Country | App. No. | Our Ref. |
Filed | Patent No./ Publication No. |
Grant Date/ Pub. Date |
Next Renewal | ||||||
| “[***]” | “[***]” | “[***]” | “[***]” |
| 10.Patent | Intec Pharma Ltd. “[***]” |
| Country | App. No. | Our Ref. |
Filed | Patent No./ Publication No. |
Grant Date/ Pub. Date |
Next Renewal | ||||||
| “[***]” | “[***]” | “[***]” | “[***]” |
NOTE: PORTIONS OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF THE REDACTED LANGUAGE.
Exhibit 1.5 (a)
| 1.Patent | Yissum Research Development Company of the Hebrew University of Jerusalem Gastroretentive Controlled Release Pharmaceutical Dosage Forms -(Client Case:IN-1-IL) - (0047465) |
| Country | App. No. | Our Ref. |
Filed | Patent No./ Publication No. |
Grant Date/ Pub. Date |
Next Renewal | ||||||
| Israel | 149853 | 1634914 | 20/11/2000 | 149853 | 01/04/2007 | 20/11/2018 | ||||||
| Patent Cooperation Treaty | PCT/IL00/00774 | 1635077 | 20/11/2000 | WO 01/37812 | 31/05/2001 | |||||||
| Australia | 16477/01 | 1635101 | 20/11/2000 | 783062 | 05/01/2006 | 20/11/2015 | ||||||
| Canada | 2,392,361 | 1635119 | 20/11/2000 | 2,392,361 | 19/01/2010 | 20/11/2015 | ||||||
| Japan | 2001-539427 | 0000000 | 20/11/2000 | 4679020 | 10/02/2011 | 10/02/2015 | ||||||
| United States of America | 10/157,325 | 1635143 | 20/11/2000 | 6,685,962 | 03/02/2004 | 03/08/2015 | ||||||
| South Africa | 200204268 | 1635150 | 20/11/2000 | 2002/4268 | 26/11/2003 | 20/11/2015 | ||||||
| European Patent Office | 00978993.4 | 1635168 | 20/11/2000 | 1235557 | 27/07/2005 | |||||||
| France | 00978993.4 | 1635572 | 20/11/2000 | 1235557 | 27/07/2005 | 30/11/2015 | ||||||
| Germany | 00978993.4 | 1635580 | 20/11/2000 | 60021604 | 27/07/2005 | 30/11/2015 | ||||||
| Spain | 00978993.4 | 1635598 | 20/11/2000 | 1235557 | 27/07/2005 | 30/11/2015 | ||||||
| Switzerland | 00978993.4 | 1635606 | 20/11/2000 | EP1235557 | 27/07/2005 | 30/11/2015 | ||||||
| Ireland | 00978993.4 | 1635630 | 20/11/2000 | 1235557 | 27/07/2005 | 30/11/2015 | ||||||
| Italy | 00978993.4 | 1635648 | 20/11/2000 | 1235557 | 27/07/2005 | 30/11/2015 | ||||||
| United Kingdom | 00978993.4 | 1635655 | 20/11/2000 | 1235557 | 27/07/2005 | 30/11/2015 |
NOTE: PORTIONS OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF THE REDACTED LANGUAGE.
Exhibit 1.5 (b)
| 2.Patent | Intec Pharma Ltd. Method and Apparatus for Forming Delivery Devices for Oral Intake of an Agent -(Client Case:IN-3-USP) -(0047512) |
| Country | App. No. | Our Ref. |
Filed | Patent No./ Publication No. |
Grant Date/ Pub. Date |
Next Renewal | ||||||
| United States of America | 60/759,554 | 1636661 | 18/01/2006 | |||||||||
| Patent Cooperation Treaty | IL2007/000070 | 1724418 | 18/01/2007 | WO2007/083309 | 26/07/2007 | |||||||
| European Patent Office | 07700757.3 | 1853217 | 18/01/2007 | 1981465 | 22/10/2008 | 31/01/2015 | ||||||
| Canada | 2,637,655 | 1853225 | 18/01/2007 | 18/01/2015 | ||||||||
| Israel | 192896 | 1853233 | 18/01/2007 | 192896 | 28/09/2013 | 18/01/2017 | ||||||
| Japan | 2008-550909 | 0000000 | 18/01/2007 | 5399715 | 01/11/2013 | 01/11/2016 | ||||||
| United States of America | 12/087,888 | 1853258 | 18/01/2007 | 8,298,574 | 30/10/2012 | 30/04/2016 | ||||||
| United States of America | 13/613,718 | 2181500 | 18/01/2007 | 8,753,678 | 17/06/2014 | 17/12/2017 | ||||||
| United States of America | 13/800,471 | 2214433 | 18/01/2007 | 8,609,136 | 17/12/2013 | 17/06/2017 | ||||||
| Japan | 2013-054912 | 0000000 | 18/01/2007 | 2013-129669 | 04/07/2013 | |||||||
| Israel | 226561 | 2228767 | 18/01/2007 | |||||||||
| Israel | 226563 | 2229192 | 18/01/2007 | |||||||||
| Israel | 226564 | 2229205 | 18/01/2007 | |||||||||
| United States of America | 14/305,600 | 2275337 | 18/01/2007 |
US-2014-0360132 |
11/12/2014 |
NOTE: PORTIONS OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF THE REDACTED LANGUAGE.
| 3.Patent | Intec Pharma Ltd. A Gastro-Retentive System for the Delivery of Macromolecules -(Client Case:IN-4-USP) -(0047513) |
| Country | App. No. | Our Ref. |
Filed | Patent No./ Publication No. |
Grant Date/ Pub. Date |
Next Renewal | ||||||
| United States of America | 60/773,316 | 1636679 | 15/02/2006 | |||||||||
| Patent Cooperation Treaty | IL2007/000212 | 1731967 | 15/02/2007 | WO2007/093999 | 23/08/2007 | |||||||
| European Patent Office | 07713260.3 | 1859727 | 15/02/2007 | 1991210 | 19/11/2008 | 28/02/2015 | ||||||
| Canada | 2,642,479 | 1859735 | 15/02/2007 | 2,642,479 | 19/08/2014 | 15/02/2015 | ||||||
| Israel | 193450 | 1859743 | 15/02/2007 | |||||||||
| United States of America | 12/223,965 | 1859750 | 15/02/2007 |
US-2009-0304768 |
10/12/2009 |
NOTE: PORTIONS OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF THE REDACTED LANGUAGE.
| 4.Patent | Intec Pharma Ltd. Carbidopa/Lipodopa Gastroretentive Drug Delivery -(Client Case:IN-7-IL) -(060812) |
| Country | App. No. | Our Ref. |
Filed | Patent No./ Publication No. |
Grant Date/ Pub. Date |
Next Renewal | ||||||
| Israel | 208708 | 2051008 | 17/04/2009 | |||||||||
| United States of America | 12/937,955 | 2144590 | 17/04/2009 | 8,771,730 | 08/07/2014 | 08/01/2018 | ||||||
| Patent Cooperation Treaty | PCT/IB2009/005691 | 2153336 | 17/04/2009 | WO2009/144558 | ||||||||
| Canada | 2,721,493 | 2153341 | 17/04/2009 | 17/04/2015 | ||||||||
| China | 200980120103.9 | 2153353 | 17/04/2009 | CN102149369A | 10/08/2011 | |||||||
| European Patent Office | 09754186.6 | 2153363 | 17/04/2009 | 2276473 | 26/01/2011 | 30/04/2015 | ||||||
| India | 7638/DELNP/2010 | 2153372 | 17/04/2009 | |||||||||
| Japan | 2011-504573 | 0000000 | 17/04/2009 | |||||||||
| Japan | 0000000 | |||||||||||
| Republic of Korea | 00-0000-0000000 | 2153405 | 17/04/2009 | |||||||||
| South Africa | 2010/07797 | 2153411 | 17/04/2009 | 2010/07797 | 27/07/2011 | 17/04/2015 | ||||||
| Hong Kong | 11113197.1 | 2153823 | 17/04/2009 | 1158545 | 20/07/2012 | 17/04/2018 | ||||||
| United States of America | 14/322,436 | 2286884 | 17/04/2009 |
US-2014-0314842 |
23/10/2014 |
NOTE: PORTIONS OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF THE REDACTED LANGUAGE.
| 4.Patent | Intec Pharma Ltd. Carbidopa/Lipodopa Gastroretentive Drug Delivery -(Client Case:IN-7-IL) -(060812) |
| Country | App. No. | Our Ref. |
Filed | Patent No./ Publication No. |
Grant Date/ Pub. Date |
Next Renewal | ||||||
| United States of America | 14/322,460 | 2286894 | 17/04/2009 |
US-2015-0010624 |
08/01/2015 |
| 5.Patent | Intec Pharma Ltd. ZALEPLON GASTRORETENTIVE DRUG DELIVERY SYSTEM -(Client Case:IN-8-IL) -(060811) |
| Country | App. No. | Our Ref. |
Filed | Patent No./ Publication No. |
Grant Date/ Pub. Date |
Next Renewal | ||||||
| Israel | 213376 | 2127779 | 19/10/2009 | |||||||||
|
Patent Cooperation Treaty |
PCT/IB2009/007731 | 2153230 | 19/10/2009 | WO2010/064139 | ||||||||
| China | 200980153943.5 | 2153258 | 19/10/2009 | CN102300463A | 28/12/2011 | 19/10/2014 | ||||||
| European Patent Office | 09830077.5 | 2153268 | 19/10/2009 | 2378883 | 26/10/2011 | 31/10/2014 | ||||||
| India | 5067/DELNP/2011 | 2153278 | 19/10/2009 | |||||||||
| South Africa | 2011/04620 | 2153314 | 19/10/2009 | 2011/04620 | 28/03/2012 | 19/10/2015 |
NOTE: PORTIONS OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF THE REDACTED LANGUAGE.
| 5.Patent | Intec Pharma Ltd. ZALEPLON GASTRORETENTIVE DRUG DELIVERY SYSTEM -(Client Case:IN-8-IL) -(060811) |
| Country | App. No. | Our Ref. |
Filed | Patent No./ Publication No. |
Grant Date/ Pub. Date |
Next Renewal | ||||||
| United States of America | 13/132,899 | 2153326 | 19/10/2009 |
US-2012-0021051 |
26/01/2012 | |||||||
| Japan | 2014-231788 | 0000000 | 19/10/2009 |
| 6.Patent | Intec Pharma Ltd. Accordion pill comprising levodopa for an improved treatment of Xxxxxxxxx’x Disease symptoms -(Client Case:IN-11-USP) -(060810) |
| Country | App. No. | Our Ref. |
Filed | Patent No./ Publication No. |
Grant Date/ Pub. Date |
Next Renewal | ||||||
| United States of America | 61/408,985 | 2153012 | 01/11/2010 | |||||||||
| Patent Cooperation Treaty | PCT/IB2011/002888 | 2153034 | 01/11/2011 | WO2012/059815 | 10/05/2012 | |||||||
| Canada | 2,815,959 | 2222633 | 01/11/2011 | 01/11/2015 | ||||||||
| European Patent Office | 11805936.9 | 2222641 | 01/11/2011 | 2635272 | 11/09/2013 | 30/11/2015 | ||||||
| India | 4158/DELNP/2013 | 2222652 | 01/11/2011 | |||||||||
| Israel | 226000 | 2222662 | 01/11/2011 |
NOTE: PORTIONS OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF THE REDACTED LANGUAGE.
| 6.Patent | Intec Pharma Ltd. Accordion pill comprising levodopa for an improved treatment of Xxxxxxxxx’x Disease symptoms -(Client Case:IN-11-USP) -(060810) |
| Country | App. No. | Our Ref. |
Filed | Patent No./ Publication No. |
Grant Date/ Pub. Date |
Next Renewal | ||||||
| United States of America | 13/882,768 | 2222675 | 01/11/2011 |
US-2014- 0017303 |
16/01/2014 |
| 7.Patent | Intec Pharma Ltd. “[***]” |
| Country | App. No. | Our Ref. |
Filed | Patent No./ Publication No. |
Grant Date/ Pub. Date |
Next Renewal | ||||||
| “[***]” | “[***]” | “[***]” | “[***]” |
| 8.Patent | Intec Pharma Ltd. “[***]” |
| Country | App. No. | Our Ref. |
Filed | Patent No./ Publication No. |
Grant Date/ Pub. Date |
Next Renewal | ||||||
| “[***]” | “[***]” | “[***]” | “[***]” |
| 9.Patent | Intec Pharma Ltd. “[***]” |
| Country | App. No. | Our Ref. |
Filed | Patent No./ Publication No. |
Grant Date/ Pub. Date |
Next Renewal | ||||||
| “[***]” | “[***]” | “[***]” | “[***]” |
NOTE: PORTIONS OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF THE REDACTED LANGUAGE.
| 10.Patent | Intec Pharma Ltd. “[***]” |
| Country | App. No. | Our Ref. |
Filed | Patent No./ Publication No. |
Grant Date/ Pub. Date |
Next Renewal | ||||||
| “[***]” | “[***]” | “[***]” | “[***]” |
